Media.Player

Quantitative EEG (QEEG) Method to Identify Individuals at Risk for Adverse Antidepressant Effects

詳細技術說明

The invention utilizes output from quantitative electroencephalographic (QEEG) recordings for an individual that are obtained at two time-points: baseline (T1; prior to the start of drug) and (T2; early in the course of antidepressant treatment). From these recordings, a single measure is generated that can be used to determine the chance or percent likelihood that the individual will experience medication-related increases in anxiety, agitation, hostility, and/or suicidal ideation during continuation of the specific antidepressant over the subsequent two months.

*Abstract

This invention is a method that uses human EEG output to determine, early in the course of antidepressant treatment, whether an individual has an elevated risk of developing adverse medication effects. In the clinical setting, this method will provide a neurophysiologic marker, early during antidepressant treatment, that will help determine one’s risk of experiencing anxiety, agitation, hostility, and/or increases in suicidal ideation with continuation of that medication.  

*IP Issue Date

Aug 27, 2013

*Principal Investigation

Name: Ian Cook

Department:

Name: Aimee Hunter

Department:

Name: Andrew Leuchter

Department:

附加資料

Patent Number: US8521270B2
Application Number: US2008303239A
Inventor: Hunter, Aimee M. | Leuchter, Andrew F.
Priority Date: 5 Jun 2006
Priority Number: US8521270B2
Application Date: 17 Sep 2009
Publication Date: 27 Aug 2013
IPC Current: A61B000504
US Class: 600544
Assignee Applicant: The Regents of the University of California
Title: Quantitative EEG method to identify individuals at risk for adverse antidepressant effects
Usefulness: Quantitative EEG method to identify individuals at risk for adverse antidepressant effects
Summary: A method of identifying subjects at risk for adverse effects from a psychotropic or central nervous system (CNS) active treatment such as antidepressant treatment, e.g., within two days of initiating antidepressant treatment determine one's risk of experiencing increased anxiety, agitation, hostility, and/or suicidal ideation with continuation of that medication. It determines one's risk of experiencing overall clinical worsening of depressive symptoms with continuation of that medication. It determines the safety of putative antidepressant and other psychotropic compounds at various doses.
Novelty: Risk identification method for a psychotropic treatment involves determining change in cordance before and after two days of treatment by calculating a difference between the two resultant values calculated using two sets of physical values

主要類別

診斷/治療

細分類別

其他疾病

申請號碼

8521270

其他

State Of Development

In data from depressed patients randomized to antidepressant treatment, our QEEG biomarker predicted worsening suicidal ideation with 97% accuracy (80% sensitivity, 100% specificity) and .86 Area under the Receiver Operating Curve. (These results need to be prospectively replicated in independent samples.) The biomarker did not predict suicidal worsening among depressed subjects treated with placebo.

Tech ID/UC Case

23372/2006-262-0

Related Cases

2006-262-0

國家/地區

美國